{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:56:04Z","timestamp":1791640564189,"version":"4.3.4"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T00:00:00Z","timestamp":1611878400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004896","name":"Eisai Incorporated","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004896","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Sleep Medicine"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.sleep.2021.01.048","type":"journal-article","created":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T12:47:38Z","timestamp":1612270058000},"page":"333-342","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":87,"special_numbering":"C","title":["Long-term effectiveness and safety of lemborexant in adults with insomnia disorder: results from a phase 3 randomized clinical trial"],"prefix":"10.1016","volume":"80","author":[{"given":"Jane","family":"Yardley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikko","family":"K\u00e4rpp\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7414-9017","authenticated-orcid":false,"given":"Yuichi","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Pinner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Perdomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gleb","family":"Filippov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Moline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.sleep.2021.01.048_bib1","doi-asserted-by":"crossref","first-page":"307","DOI":"10.5664\/jcsm.6470","article-title":"Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline","volume":"13","author":"Sateia","year":"2017","journal-title":"J\u00a0Clin Sleep Med"},{"key":"10.1016\/j.sleep.2021.01.048_bib2","doi-asserted-by":"crossref","first-page":"343","DOI":"10.5665\/sleep.3410","article-title":"National use of prescription medications for insomnia: NHANES 1999-2010","volume":"37","author":"Bertisch","year":"2014","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2021.01.048_bib3","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1093\/sleep\/33.2.225","article-title":"A\u00a012-week, randomized, double-blind, placebo-controlled study evaluating the effect of eszopiclone 2 mg on sleep\/wake function in older adults with primary and comorbid insomnia","volume":"33","author":"Ancoli-Israel","year":"2010","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2021.01.048_bib4","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.4088\/JCP.v65n0816","article-title":"Long-term, non-nightly administration of zolpidem in the treatment of patients with primary insomnia","volume":"65","author":"Perlis","year":"2004","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.sleep.2021.01.048_bib5","first-page":"114","article-title":"Zaleplon, A novel nonbenzodiazepine hypnotic, effectively treats insomnia in elderly patients without causing rebound effects","volume":"1","author":"Ancoli-Israel","year":"1999","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"10.1016\/j.sleep.2021.01.048_bib6","doi-asserted-by":"crossref","first-page":"536","DOI":"10.4088\/JCP.v60n0806","article-title":"Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. Zaleplon Clinical Study Group","volume":"60","author":"Elie","year":"1999","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.sleep.2021.01.048_bib7","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/sleep\/31.1.79","article-title":"Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study","volume":"31","author":"Krystal","year":"2008","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2021.01.048_bib8","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.sleep.2005.06.004","article-title":"An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia","volume":"6","author":"Roth","year":"2005","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2021.01.048_bib9","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/jsr.12594","article-title":"European guideline for the diagnosis and treatment of insomnia","volume":"26","author":"Riemann","year":"2017","journal-title":"J\u00a0Sleep Res"},{"key":"10.1016\/j.sleep.2021.01.048_bib10","doi-asserted-by":"crossref","first-page":"487","DOI":"10.5664\/jcsm.27286","article-title":"Clinical guideline for the evaluation and management of chronic insomnia in adults","volume":"4","author":"Schutte-Rodin","year":"2008","journal-title":"J\u00a0Clin Sleep Med"},{"key":"10.1016\/j.sleep.2021.01.048_bib11","first-page":"43","article-title":"Deprescribing benzodiazepine receptor agonists taken for insomnia: a review and key messages from practice guidelines","volume":"129","author":"Lee","year":"2019","journal-title":"Pol Arch Intern Med"},{"key":"10.1016\/j.sleep.2021.01.048_bib12","first-page":"339","article-title":"Deprescribing benzodiazepine receptor agonists: evidence-based clinical practice guideline","volume":"64","author":"Pottie","year":"2018","journal-title":"Can Fam Physician"},{"key":"10.1016\/j.sleep.2021.01.048_bib13","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S1087-0792(97)90012-5","article-title":"Hyperarousal and insomnia","volume":"1","author":"Bonnet","year":"1997","journal-title":"Sleep Med Rev"},{"key":"10.1016\/j.sleep.2021.01.048_bib14","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1378\/chest.14-1617","article-title":"The pathophysiology of insomnia","volume":"147","author":"Levenson","year":"2015","journal-title":"Chest"},{"key":"10.1016\/j.sleep.2021.01.048_bib15","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3389\/fphar.2013.00163","article-title":"Orexin receptor antagonists as therapeutic agents for insomnia","volume":"4","author":"Equihua","year":"2013","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.sleep.2021.01.048_bib16","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.biopsych.2014.10.003","article-title":"Suvorexant in patients with insomnia: results from two 3-month randomized controlled clinical trials","volume":"79","author":"Herring","year":"2016","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.sleep.2021.01.048_bib17","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1474-4422(14)70053-5","article-title":"Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial","volume":"13","author":"Michelson","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.sleep.2021.01.048_bib18","first-page":"41","article-title":"Efficacy and safety of suvorexant for the treatment of primary insomnia among Chinese: a 6-month randomized double-blind controlled study","volume":"22","author":"Fan","year":"2017","journal-title":"Neurol Asia"},{"key":"10.1016\/j.sleep.2021.01.048_bib19","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1124\/jpet.117.241422","article-title":"In\u00a0vitro and in silico characterization of lemborexant (E2006), a novel dual orexin receptor antagonist","volume":"362","author":"Beuckmann","year":"2017","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.sleep.2021.01.048_bib20","series-title":"Dayvigo (lemborexant) tablets [package insert]","year":"2019"},{"key":"10.1016\/j.sleep.2021.01.048_bib21","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.5664\/jcsm.6800","article-title":"Lemborexant, a dual orexin receptor antagonist (DORA) for the treatment of insomnia disorder: results from a Bayesian, adaptive, randomized, double-blind, placebo-controlled study","volume":"13","author":"Murphy","year":"2017","journal-title":"J\u00a0Clin Sleep Med"},{"key":"10.1016\/j.sleep.2021.01.048_bib22","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.18254","article-title":"Comparison of lemborexant with placebo and zolpidem tartrate extended release for the treatment of older adults with insomnia disorder: a phase 3 randomized clinical trial","volume":"2","author":"Rosenberg","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.sleep.2021.01.048_bib23","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/zsaa123","article-title":"Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE-2","author":"K\u00e4rpp\u00e4","year":"2020","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2021.01.048_bib24","series-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2013"},{"key":"10.1016\/j.sleep.2021.01.048_bib25","doi-asserted-by":"crossref","first-page":"E115","DOI":"10.1111\/j.1464-410X.2012.11489.x","article-title":"Cumulative response curves to enhance interpretation of treatment differences on the Self-Esteem and Relationship questionnaire for men with erectile dysfunction","volume":"111","author":"Cappelleri","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.sleep.2021.01.048_bib26","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1745-6215-8-31","article-title":"Responder analyses and the assessment of a clinically relevant treatment effect","volume":"8","author":"Snapinn","year":"2007","journal-title":"Trials"},{"key":"10.1016\/j.sleep.2021.01.048_bib27","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0165-0327(90)90009-W","article-title":"The benzodiazepine withdrawal symptom questionnaire","volume":"19","author":"Tyrer","year":"1990","journal-title":"J\u00a0Affect Disord"},{"key":"10.1016\/j.sleep.2021.01.048_bib28","doi-asserted-by":"crossref","DOI":"10.1111\/jsr.12997","article-title":"Dynamic features of placebo effects addressing persistent insomnia disorder: a meta-analysis of placebo-controlled randomized clinical trials","volume":"29","author":"Jiang","year":"2020","journal-title":"J\u00a0Sleep Res"},{"key":"10.1016\/j.sleep.2021.01.048_bib29","first-page":"925","article-title":"Effect of placebo conditions on polysomnographic parameters in primary insomnia: a meta-analysis","volume":"38","author":"Winkler","year":"2015","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2021.01.048_bib30","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s40268-017-0207-7","article-title":"Benzodiazepines and Z-drugs: an updated review of major adverse outcomes reported on in epidemiologic research","volume":"17","author":"Brandt","year":"2017","journal-title":"Drugs R D"},{"key":"10.1016\/j.sleep.2021.01.048_bib31","author":"US Food and Drug Administration"},{"key":"10.1016\/j.sleep.2021.01.048_bib32","doi-asserted-by":"crossref","first-page":"467","DOI":"10.4088\/JCP.07m03834","article-title":"Safety and subjective sleep effects of ramelteon administration in adults and older adults with chronic primary insomnia: a 1-year, open-label study","volume":"70","author":"Richardson","year":"2009","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.sleep.2021.01.048_bib33","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1097\/ALN.0b013e31816d83e4","article-title":"STOP questionnaire: a tool to screen patients for obstructive sleep apnea","volume":"108","author":"Chung","year":"2008","journal-title":"Anesthesiology"},{"key":"10.1016\/j.sleep.2021.01.048_bib34","doi-asserted-by":"crossref","DOI":"10.1111\/jsr.13021","article-title":"Respiratory safety of lemborexant in healthy adult and elderly subjects with mild obstructive sleep apnea: a randomized, double-blind, placebo-controlled, crossover study","volume":"29","author":"Cheng","year":"2020","journal-title":"J\u00a0Sleep Res"},{"key":"10.1016\/j.sleep.2021.01.048_bib35","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.sleep.2005.12.011","article-title":"The reliability, validity and responsiveness of the International Restless Legs Syndrome Study Group rating scale and subscales in a clinical-trial setting","volume":"7","author":"Abetz","year":"2006","journal-title":"Sleep Med"}],"container-title":["Sleep Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1389945721000654?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1389945721000654?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T15:27:52Z","timestamp":1761406072000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1389945721000654"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":35,"alternative-id":["S1389945721000654"],"URL":"https:\/\/doi.org\/10.1016\/j.sleep.2021.01.048","relation":{},"ISSN":["1389-9457"],"issn-type":[{"value":"1389-9457","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term effectiveness and safety of lemborexant in adults with insomnia disorder: results from a phase 3 randomized clinical trial","name":"articletitle","label":"Article Title"},{"value":"Sleep Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.sleep.2021.01.048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Eisai Inc. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}